Local Allergic Rhinitis: Treating a Positive Nasal Challenge When Every Systemic Test Is Negative
A diagnosis a systemic allergy panel could never have caught, and a treatment decision resting on how far to trust the smaller literature that can.
Marisol T., a 34-year-old emergency-department nurse who has worked night shifts for most of her career, finally agreed to a specialist referral after her third consecutive winter of nasal congestion, clear rhinorrhea, and sneezing fits bad enough to send her home mid-shift twice this year — something her charge nurse has started noting on her file. She describes her symptoms as year-round with a clear worsening each spring, and has already tried maximized intranasal corticosteroid therapy and a second-generation oral antihistamine in combination for eight weeks with only partial benefit, confirmed adherent by her own pharmacy refill history.
Her systemic allergy workup is entirely negative — skin prick testing to a full regional aeroallergen panel and serum-specific IgE for the same panel both came back unremarkable, which would ordinarily close the allergic-rhinitis question. But local allergic rhinitis, first characterized in detail by Rondón and colleagues, describes exactly this picture: a mucosal allergic response confined to the nasal tissue, with local IgE production that a systemic skin or serum test, sampling blood and skin rather than nasal mucosa, cannot detect. A nasal allergen provocation test performed today with dust-mite extract produced an unambiguous local response — a sharp fall in nasal airflow on acoustic rhinometry alongside her symptom score, within twenty minutes of exposure — that a saline control did not, confirming the diagnosis the systemic panel had missed entirely.
Marisol's own theory, formed after years of frustration, was that her congestion simply tracked her irregular sleep schedule rather than anything environmentally triggered — a plausible read that made today's referral feel almost like a last resort. She has no other chronic medical conditions, takes no daily medications, and has never had a drug reaction of any kind, which matters directly to today's decision: nothing about her overall health profile raises independent caution about escalating either her pharmacotherapy or, eventually, immunotherapy. The nasal provocation test itself works by exposing one nasal cavity to increasing concentrations of an allergen extract while the other serves as an internal control, with objective measures — acoustic rhinometry or peak nasal inspiratory flow, alongside symptom scoring — tracked at fixed intervals; a positive result requires an objective physiologic change, not just a reported symptom, which is part of why Rondón's group considers it a genuine diagnostic test rather than a subjective add-on to a negative systemic workup.
Weighing a positive local test against a thin evidence base
Her nasal provocation result is unambiguous, and local allergic rhinitis is a real, described entity, not a diagnosis of convenience for a negative systemic workup. Rondón's group has already run a small placebo-controlled trial of dust-mite immunotherapy specifically in confirmed LAR patients and found genuine symptom and rescue-medication improvement — that's the correct population match for her, not the much larger systemic-IgE literature everyone defaults to.
I'm not disputing the nasal challenge — I'll take the diagnosis as real. What I won't do is treat one small trial as equivalent evidence to the decades of replicated data behind systemic-IgE immunotherapy before asking her to commit to years of injections.
The trial you're citing is real, but it's a fraction of the size, and generalizing from it the way you're proposing asks her to carry a burden the evidence hasn't actually earned yet.
Both of you are actually arguing about two different decisions as if they were one. Diagnosing LAR and escalating specifically to immunotherapy don't have to be resolved on the same visit — the nasal challenge is good enough to justify treating her as genuinely allergic and escalating pharmacotherapy meaningfully beyond where she already is.
Immunotherapy is the larger, harder-to-reverse commitment resting on the thinner evidence base; sequencing pharmacotherapy escalation first costs her little if it works, and if it doesn't, the immunotherapy conversation happens on stronger footing — a documented pharmacotherapy failure, not just a positive challenge.
Agreed: escalate to combination intranasal therapy today and reassess in 8–12 weeks before revisiting immunotherapy, on the shared premise that the diagnosis itself — local allergic rhinitis — is not in real dispute.
Not agreed, and left open rather than smoothed over: whether the sequencing itself was necessary, or whether it simply delays a treatment she's already earned. The allergist would have offered immunotherapy today on the strength of the published LAR trial; the primary care physician and pharmacologist both wanted pharmacotherapy exhausted first given how much larger a commitment immunotherapy represents relative to the size of its specific supporting evidence.